FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $784,000 | -36.1% | 31,652 | 0.0% | 0.03% | -27.9% |
| Q1 2022 | $1,227,000 | -71.2% | 31,652 | -56.5% | 0.04% | -68.6% |
| Q4 2021 | $4,255,000 | -1.3% | 72,727 | 0.0% | 0.14% | -1.4% |
| Q3 2021 | $4,311,000 | -31.7% | 72,727 | 0.0% | 0.14% | -32.2% |
| Q2 2021 | $6,312,000 | -49.1% | 72,727 | -51.6% | 0.20% | -51.9% |
| Q1 2021 | $12,396,000 | -18.0% | 150,343 | -9.6% | 0.43% | -19.8% |
| Q4 2020 | $15,123,000 | +74.0% | 166,317 | -23.5% | 0.53% | +62.9% |
| Q3 2020 | $8,692,000 | +36.5% | 217,462 | +17.1% | 0.33% | +34.7% |
| Q2 2020 | $6,370,000 | +73.1% | 185,672 | +12.1% | 0.24% | +45.8% |
| Q1 2020 | $3,680,000 | +13.5% | 165,672 | 0.0% | 0.17% | +35.0% |
| Q4 2019 | $3,242,000 | +26.0% | 165,672 | 0.0% | 0.12% | +9.8% |
| Q3 2019 | $2,573,000 | +419.8% | 165,672 | +579.6% | 0.11% | +460.0% |
| Q2 2019 | $495,000 | – | 24,379 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |